No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Healthcare Information Services
Optomed Oyj, established in 2004 and headquartered in Oulu, Finland, is a medical technology company specializing in the development, production, and sale of portable devices for retinal examination and advanced screening software. The company operates globally, with a presence in Finland and China, structured into dedicated Devices and Software segments. Its Device division focuses on fundus cameras, serving a broad spectrum of medical specialists, including ophthalmologists, pediatricians, endocrinologists, neurologists, and general practitioners. These camera products are marketed under Optomed's own brand names such as Optomed Smartscope Pro, Aurora, Polaris, and Halo, and are also provided as OEM products under labels including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal. The Software segment offers a comprehensive suite of solutions. For eye health, this includes Avenue Eye Screen for managing the workflow of eye disease screening and monitoring (like diabetic retinopathy), Avenue Archive for healthcare data storage and transmission, Avenue Telemedicine for remote image analysis, Avenue AI for automated diabetic retinopathy screening, and Avenue Sync for seamless integration of fundus cameras with hospital systems. Beyond eye care, Optomed provides Avenue Cancer Screen for managing breast, cervical, and colorectal cancer screenings; Optomed RIS for optimizing diagnostic processes in healthcare imaging units; Sectra PACS, a scalable system for high-volume healthcare providers; Optomed Service Portal for supporting imaging service operations; Facad for visible light imaging and cephalometric tracing; and Sectra PACS Pathology, a digital solution for the distribution and diagnosis of scanned glass slides. Furthermore, Optomed extends professional IT consulting services to government bodies. The company's products and solutions are distributed through OEMs, authorized distributors, and its direct sales channels. Its primary clientele includes hospitals, specialized eye clinics, and both independent and chain optician stores.
www.optomed.comNo one on the platform currently holds OPTOMED.HE.
No tracked institution reports a position in OPTOMED.HE as of their last filing.
No one on the platform has traded OPTOMED.HE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 13.7% | 5.6% | ||||
| Profit Margin % | -38.8% | -34.1% | -30.6% | |||
| Free Cash Flow Margin % | -28.3% | -29.4% | -28.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $18M | +3.1% | $-0.15 | $-0.18–$-0.13 | — | 2 |
| 2027 | $21M | +16.8% | $-0.11 | $-0.11–$-0.10 | — | 1 |
| 2028 | $25M | +21.4% | $-0.04 | $-0.04–$-0.04 | — | 1 |
| 2029 | $24M | -3.6% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $-0.05 | $-0.04 | +22.7% |
| 2026-05-06 | $-0.05 | $-0.05 | +0.0% |
| 2026-02-10 | $-0.09 | $-0.09 | +0.0% |
| 2025-11-06 | $-0.08 | $-0.08 | +2.3% |
| 2025-08-07 | $-0.05 | $-0.08 | -67.6% |
| 2025-05-06 | $-0.09 | $-0.08 | +11.1% |
| 2025-02-13 | $-0.04 | $-0.05 | -25.0% |
| 2024-11-07 | $-0.07 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| OPTOMED.HEOptomed Oyj | $1.58 | -0.13% | $34M | — |
| BIOBV.HEBiohit Oyj | $2.38 | -0.42% | $36M | — |
| HRTIS.HEHerantis Pharma Oyj | $1.41 | -1.40% | $37M | — |
| MODU.HEModulight Oyj | $1.14 | +12.32% | $48M | — |
| NANOFH.HENanoform Finland Oyj | $0.86 |
| $-0.09 |
| -28.6% |
| +1.17% |
| $74M |
| — |
| NXTMH.HENexstim Plc | $9.70 | -0.51% | $70M | — |
Source: Financial Modeling Prep · peers by sector/industry